Trial · NCT00184054
Results by group11
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 11 of 11
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi) | Arsenic Trioxide (ATO) Plus Ascorbic Acid | CR | 1 | participants | |
| Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi) | Arsenic Trioxide (ATO) Plus Ascorbic Acid | CRi | 5 | participants | |
| Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi) | Arsenic Trioxide (ATO) Plus Ascorbic Acid | Treatment Failure | 4 | participants | |
| Number of Participants With a Response (Complete Remissions (CR) and Complete Remission With Incomplete Blood Count Recovery (CRi) | Arsenic Trioxide (ATO) Plus Ascorbic Acid | Not Evaluable | 1 | participants | |
| Number of Participants With Severe (Grades 3-5) Adverse Events | Arsenic Trioxide (ATO) Plus Ascorbic Acid | Anorexia | 1 | Participants | |
| Number of Participants With Severe (Grades 3-5) Adverse Events | Arsenic Trioxide (ATO) Plus Ascorbic Acid | Alanine aminotransferase increased | 1 | Participants | |
| Number of Participants With Severe (Grades 3-5) Adverse Events | Arsenic Trioxide (ATO) Plus Ascorbic Acid | Conjunctivitis infective | 2 | Participants | |
| Number of Participants With Severe (Grades 3-5) Adverse Events | Arsenic Trioxide (ATO) Plus Ascorbic Acid | Differentiation syndrome | 1 | Participants | |
| Number of Participants With Severe (Grades 3-5) Adverse Events | Arsenic Trioxide (ATO) Plus Ascorbic Acid | Electrocardiogram QT corrected interval prolonged | 1 | Participants | |
| Number of Participants With Severe (Grades 3-5) Adverse Events | Arsenic Trioxide (ATO) Plus Ascorbic Acid | Neuropathy: sensory | 1 | Participants | |
| Number of Participants With Severe (Grades 3-5) Adverse Events | Arsenic Trioxide (ATO) Plus Ascorbic Acid | Sepsis | 4 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00184054/results